Seres Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 23.12K shares.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 782.00 shares.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 23.90K shares.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 326.86K shares, a 0.68% decline from fiscal 2021.
- Seres Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 329.11K shares, a 85.14% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 23.90K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-05 | 23.90K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 23.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 23.90K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 782.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 782.00 shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 0.00 shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 0.00 shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 155.05K shares derived: sum of 4 quarters · filed 2024-08-15 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-08 | 204.12K shares derived: sum of 4 quarters · filed 2024-08-15 |
| 2023-12-31 | 0.00 shares derived: 8-K 12 month − 10-Q 9 month · filed 2024-08-15 | 260.64K shares 8-K · filed 2024-08-15 |
| 2023-09-30 | 155.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 305.34K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 49.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 300.77K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 56.52K shares 10-Q · filed 2023-05-09 | 290.91K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 44.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | 326.86K shares 10-K · filed 2023-03-07 |
| 2022-09-30 | 150.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 329.61K shares derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | 39.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 231.07K shares derived: sum of 4 quarters · filed 2022-08-03 |
| 2022-03-31 | 92.48K shares 10-Q · filed 2022-05-04 | 317.41K shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 47.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 329.11K shares 10-K · filed 2022-03-01 |
| 2021-09-30 | 51.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 526.37K shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 125.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 2.30M shares derived: sum of 4 quarters · filed 2021-08-03 |
| 2021-03-31 | 104.18K shares 10-Q · filed 2021-05-04 | 2.21M shares derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | 244.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | 2.21M shares 10-K · filed 2021-03-02 |
| 2020-09-30 | 1.83M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 1.97M shares derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | 30.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | 193.28K shares derived: sum of 4 quarters · filed 2020-07-28 |
| 2020-03-31 | 110.97K shares 10-Q · filed 2020-05-07 | 162.97K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | 90.13K shares 10-K · filed 2020-03-02 |
| 2019-09-30 | 52.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | 105.86K shares derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 110.30K shares derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | 38.13K shares 10-Q · filed 2019-05-02 | 202.31K shares derived: sum of 4 quarters · filed 2019-05-02 |
| 2018-12-31 | 15.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | 212.24K shares 10-K · filed 2019-03-06 |
| 2018-09-30 | 56.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 214.01K shares derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | 92.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | 258.17K shares derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | 48.05K shares 10-Q · filed 2018-05-09 | 191.31K shares derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | 17.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | 174.39K shares 10-K · filed 2018-03-08 |
| 2017-09-30 | 100.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | 156.89K shares derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-06-30 | 25.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | 552.88K shares derived: sum of 4 quarters · filed 2017-08-03 |
| 2017-03-31 | 31.13K shares 10-Q · filed 2017-05-04 | 1.17M shares derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | 1.27M shares 10-K · filed 2017-03-16 |
| 2016-09-30 | 496.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | 1.30M shares derived: sum of 4 quarters · filed 2016-11-10 |
| 2016-06-30 | 640.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | 805.26K shares derived: sum of 4 quarters · filed 2016-08-11 |
| 2016-03-31 | 136.69K shares 10-Q · filed 2016-05-16 | |
| 2015-12-31 | 26.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 232.97K shares 10-K · filed 2016-03-14 |
| 2015-09-30 | 1.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |